mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)

Am J Hematol. 2008 Aug;83(8):688-9. doi: 10.1002/ajh.21216.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Disease Progression
  • Drug Therapy, Combination
  • Female
  • Herpesvirus 4, Human*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Lymphoproliferative Disorders / drug therapy
  • Lymphoproliferative Disorders / virology*
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Protein Kinases
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases
  • Treatment Failure
  • Viremia / drug therapy*

Substances

  • Immunoglobulins, Intravenous
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus
  • Methylprednisolone